{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:27:04Z","timestamp":1790735224541,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.micpath.2022.105563","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:17:35Z","timestamp":1651490255000},"page":"105563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The comparison of lytic activity of isolated phage and commercial Intesti bacteriophage on ESBL producer E. coli and determination of Ec_P6 phage efficacy with in vivo Galleria mellonella larvae model"],"prefix":"10.1016","volume":"167","author":[{"given":"Hilal Basak","family":"Erol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9722-4267","authenticated-orcid":false,"given":"Banu","family":"Kaskatepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukran","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Safi Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2022.105563_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vetmic.2019.03.025","article-title":"Diversity in prevalence and characteristics of ESBL\/pAmpC producing E. coli in food in Germany","volume":"233","author":"Kaesbohrer","year":"2019","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","article-title":"Phage therapy-history from Twort and d'Herelle through soviet experience to current approaches","volume":"83","author":"Chanishvili","year":"2012","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.micpath.2022.105563_bib3","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jac\/dku173","article-title":"Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens","volume":"69","author":"Viertel","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2022.105563_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.micpath.2022.105563_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.01383","article-title":"'Get in early'; biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages","volume":"7","author":"Nale","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1556\/018.68.2017.4.11","article-title":"Chemical composition and antimicrobial activity of the commercial Origanum onites L. oil against nosocomial carbapenem resistant extended spectrum beta lactamase producer Escherichia coli isolates","volume":"68","author":"Kaskatepe","year":"2017","journal-title":"Acta Biol. Hung."},{"key":"10.1016\/j.micpath.2022.105563_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-60327-164-6_7","article-title":"Enumeration of bacteriophages by double agar overlay plaque assay","volume":"501","author":"Kropinski","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.micpath.2022.105563_bib8","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1007\/s00253-016-7858-0","article-title":"Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates","volume":"100","author":"Oliveira","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2022.105563_bib9","series-title":"Bacteriophages","author":"Adams","year":"1959"},{"key":"10.1016\/j.micpath.2022.105563_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004944","article-title":"Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials","volume":"4","author":"Merabishvili","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2022.105563_bib11","series-title":"Molecular Cloning: a Laboratory Manual","author":"Russel","year":"2001"},{"key":"10.1016\/j.micpath.2022.105563_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.micpath.2016.10.017","article-title":"Characterization of potential lytic bacteriophage against Vibrio alginolyticus and its therapeutic implications on biofilm dispersal","volume":"101","author":"Sasikala","year":"2016","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.micpath.2022.105563_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2180-10-301","article-title":"Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions","volume":"10","author":"Garbe","year":"2010","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-60327-164-6_12","article-title":"Basic phage electron microscopy","volume":"501","author":"Ackermann","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.micpath.2022.105563_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00728","article-title":"Isolation and characterization of a new phage infecting Elizabethkingia anophelis and evaluation of its therapeutic efficacy in vitro and in vivo","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2180-14-181","article-title":"Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates","volume":"14","author":"Peng","year":"2014","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib17","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00705-014-2055-x","article-title":"Efficiency of bacteriophage therapy against Cronobacter sakazakii in Galleria mellonella (greater wax moth) larvae","volume":"159","author":"Abbasifar","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.micpath.2022.105563_bib18","first-page":"50","article-title":"Effects of food on the total lipid and total fatty acid percentage of Galleria mellonella (L.) (Lepidoptera: Pyralidae) pupae","volume":"12","author":"Taskin","year":"2010","journal-title":"BA\u00dc Fen Bil Enst Dergisi"},{"key":"10.1016\/j.micpath.2022.105563_bib19","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1007\/s00253-015-6492-6","article-title":"In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients","volume":"99","author":"Olszak","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.micpath.2022.105563_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27030663","article-title":"Antifungal and anti-virulent activity of Origanum majorana L. Essential oil on Candida albicans and in vivo toxicity in the Galleria mellonella larval model","volume":"27","author":"Kaskatepe","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2022.105563_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jiph.2017.09.020","article-title":"Emergence and mechanism of carbapenem-resistant Escherichia coli in Henan, China, 2014","volume":"11","author":"Liang","year":"2018","journal-title":"J. Infect Public Heal."},{"key":"10.1016\/j.micpath.2022.105563_bib22","volume":"11","author":"Tkhilaishvili","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.00465","article-title":"Bacteriophages as potential treatment for urinary tract infections","volume":"7","author":"Sybesma","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jgar.2016.12.013","article-title":"In vitro activity of three commercial bacteriophage cocktails against multidrug-resistant Escherichia coli and Proteus spp. strains of human and non-human origin","volume":"8","author":"Bernasconi","year":"2017","journal-title":"J Glob Antimicrob Re"},{"key":"10.1016\/j.micpath.2022.105563_bib25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/jac\/dkt453","article-title":"Susceptibility of extended-spectrum- -lactamase-producing Escherichia coli to commercially available and laboratory-isolated bacteriophages","volume":"69","author":"Fitzgerald-Hughes","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2022.105563_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0966-842X(02)02459-9","article-title":"Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved","volume":"10","author":"Boyd","year":"2002","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/v10040178","article-title":"Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains","volume":"10","author":"Rohde","year":"2018","journal-title":"Viruses-Basel."},{"key":"10.1016\/j.micpath.2022.105563_bib28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3389\/fmicb.2016.01761","article-title":"In vitro effectiveness of commercial bacteriophage cocktails on diverse extended-spectrum beta-lactamase producing Escherichia coli strains","volume":"7","author":"Gundogdu","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib29","first-page":"407","article-title":"Comparison of the in vitro efficacy of commercial bacteriophage cocktails and isolated bacteriophage vB_Pa01 against carbapenem resistant nosocomial Pseudomonas aeruginosa","volume":"25","author":"Erol","year":"2021","journal-title":"J. Res. Pharm."},{"key":"10.1016\/j.micpath.2022.105563_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.02659","article-title":"Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant acinetobacter baumannii in mice","volume":"8","author":"Hua","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00029-12","article-title":"Bacteriophages phi MR299-2 and phi NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells","volume":"3","author":"Alemayehu","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.micpath.2022.105563_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/649227","article-title":"Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection","volume":"201","author":"Carmody","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2022.105563_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1086\/651135","article-title":"Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections","volume":"201","author":"Debarbieux","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2022.105563_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3389\/fmicb.2017.00981","article-title":"Editorial: phage therapy: past, present and future","volume":"8","author":"Abedon","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2022.105563_bib35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.01166-08","article-title":"Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex","volume":"53","author":"Seed","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2022.105563_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206278","article-title":"Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131","volume":"13","author":"Manohar","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2022.105563_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106200","article-title":"Bacteriophage-antibiotic combinations against ciprofloxacin\/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model","volume":"56","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2022.105563_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401022001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401022001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:39:53Z","timestamp":1760110793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401022001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"alternative-id":["S0882401022001760"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2022.105563","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The comparison of lytic activity of isolated phage and commercial Intesti bacteriophage on ESBL producer E. coli and determination of Ec_P6 phage efficacy with in vivo Galleria mellonella larvae model","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2022.105563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105563"}}